The dipeptidyl peptidase-4 inhibitor may improve the insulin secretion in type 2 diabetes patients just after starting hemodialysis treatment: preliminary study by unknown
Kawamoto et al. Renal Replacement Therapy  (2016) 2:39 
DOI 10.1186/s41100-016-0050-2RESEARCH Open AccessThe dipeptidyl peptidase-4 inhibitor may
improve the insulin secretion in type 2
diabetes patients just after starting
hemodialysis treatment: preliminary study
Shinya Kawamoto*, Ryo Koda, Yuji Imanishi, Atsunori Yoshino and Tetsuro TakedaAbstract
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become widely used in hemodialysis patients with
type 2 diabetes mellitus (T2DM). This study aimed at testing the hypothesis that administration of alogliptin, a
DPP-4i, soon after hemodialysis initiation improves beta cell function in hemodialysis patients with T2DM.
Methods: Patients with end-stage renal disease and T2DM (n = 10) not previously treated with DPP-4i (mean age,
54.2 years) were enrolled.
The study end point was the acute insulin response to glucose assessed by a frequently sampled intravenous
glucose tolerance test (IVGTT) that was conducted during the hemodialysis session just before lunch using an
external circulation circuit. All patients received 6.25 mg alogliptin for 2 weeks.
Blood glucose (Glu), serum insulin (IRI), and C-peptide (CPR) were measured before (0 min) in addition to 5 and
15 min after the glucose load. Glucagon-like peptide-1 (GLP-1) was measured before the glucose load.
Results: Glu(0) significantly decreased after the 2-week DPP-4i treatment (174 ± 20 vs. 150 ± 27 mg/dL, P = 0.023).
IRI(5) significantly increased after the DPP-4i treatment (14.6 ± 31.7 vs. 23.4 ± 16.6 μU/mL, P = 0.038), but IRI(0) and
IRI(15) did not change significantly. GLP-1 also significantly increased after the DPP-4i treatment (6.6 ± 4.4 vs. 2.6 ± 0.
8 pmol/L, P = 0.012).
Conclusions: Inhibition of DPP-4 with alogliptin improved endogenous insulin secretion in response to intravenous
glucose in hemodialysis patients with T2DM.
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Glycemic control is reported to still be important for
dialysis patients with type 2 diabetes (T2DM) to prevent
large vessel complications, such as myocardial infarction,
cerebral infarction, and peripheral artery disease, in
addition to improving survival prognosis, although their
morbidity in end-stage kidney renal disease is related to
small vessel complications [1, 2].
However, the use of oral antidiabetic drugs is typically
restricted in these patients owing to critical side effects,
such as hypoglycemia and lactic acidosis, and there have* Correspondence: kwmt@dokkyomed.ac.jp
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patients to manage because of the need for self-injection.
Dipeptidyl peptidase-4 inhibitor (DPP-4i), which is a
developed oral antidiabetic drug that does not require in-
jection, has become widely used after its reported efficacy
and safety in hemodialysis (HD) patients [3, 4].
This study aimed at evaluating the influence of DPP-4i
on insulin secretory function and the possibility that
DPP-4i can take the place of insulin in HD patients with
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Patients
Ten patients with end-stage renal disease and diabetes
(3 women, 7 men) undergoing maintenance HD as
inpatients at the Dokkyo Medical University Koshigaya
Hospital (Koshigaya, Saitama, Japan) participated in this
study between April 2012 and March 2014. All patients
provided informed consent, and the study was approved
by the Dokkyo Medical University Koshigaya Hospital
Ethics Committee (2012/1302).
Characteristics of the patients are demonstrated in
Table 1. The mean age was 54.2 ± 10.2 years, and the
mean HbA1c was 5.7 % ± 0.6 % (Table 1). The mean
urea nitrogen (UN) just before HD was 57 ± 29 mg/dL,
mean creatinine (Cr) was 8.0 ± 3.6 mg/dL, and mean
hemoglobin (Hb) was 8.5 ± 1.9 g/dL. Prior to this study,
seven patients were not receiving any antidiabetic treat-
ment. Three of the patients with previous antidiabetic
treatment participated in this study on the day after
stopping their antidiabetic treatment without rescue ther-
apy, for ethical reasons. All ten patients underwent 3 h ofTable 1 Baseline characteristics of patients (n = 10)
Characteristics Values
Age (years; mean ± SD) 54.2 ± 10.2
Gender (male/female) 7/3
BMI (mean ± SD) 23.7 ± 5.1
BP (mmHg/mean ± SD) 158 ± 21/85 ± 14
Diabetic duration (years; mean ± SD) 11.2 ± 7.9
Admission reason HD initiation (all 10 patients)
Hb (g/dL) 8.5 ± 1.9
Alb (g/dL) 2.7 ± 0.38
HbA1c (%; mean ± SD) 5.7 ± 0.6
Glycated albumin (GA) (%; mean ± SD) 17.4 ± 3.5
Fasting plasma glucose (mg/dl; mean ± SD) 117 ± 22
Postprandial plasma glucose 172 ± 20
Pre-HD plasma glucose 184 ± 14
Previous anti-diabetic agent (−): 7, alpha GI: 1, αGI +
mitiglinide: 1, insulin:1
Dialysate Kindary 2E (glucose:
100 mg/dl)
Dialyser Polysulfone (PS): 8,
cellulose triacetate(CTA): 2
HD time 3 h
Quantity of blood (QB: ml/m) 146 ± 11
Quantity of dialysate (QD: ml/m) 500
KT/V 0.73 ± 0.24
Vitamin D treatment (+):3, (−):7
Residual kidney function Urine volume 888 ± 461
(pre)→519 ± 185 (post)
Glycosuria (±):2 (+):5 (2+):3HD using Kindaly 2E dialysate (glucose, 100 mg/dL). The
dialyzer membrane was composed of polysulfone in eight
patients and cellulose triacetate in two patients. The KT/V
was 0.73 ± 0.24, which was not high because of the early
HD initiation.
Glucose tolerance test and measurements
HD commenced at approximately 9 a.m. following a
breakfast at 8 a.m., and the IVGTT was conducted
during the HD session at approximately 11 a.m., based
on the simple method by Gondo et al. [5]; the patients
did not consume any food after breakfast. Ten grams of
glucose was administered intravenously over 1 min
during the hemodialysis session using an external circu-
lation circuit. Blood glucose (Glu), serum insulin (IRI),
and C-peptide (CPR) were measured at the time before
(0), 5, and 15 min after glucose load. IRI and CPR levels
were determined using an immune-reactive method
(SRL Inc., Tokyo, Japan). Glucagon-like peptide-1 (GLP-
1) levels at 0 min were determined with an enzyme-
linked immunosorbent assay (ELISA) (SRL Inc., Tokyo,
Japan) using blood that was collected in BD™ P700 blood
collection tubes containing a proprietary DPP-4i (BD,
New Jersey, USA).
After this test, they received alogliptin benzoate (DPP-4i)
once daily. Dosage of alogliptin was reduced to 6.25 mg for
dialysis patients. Two weeks after alogliptin administration,
they underwent the same intravenous glucose tolerance
test after breakfast while undergoing alogliptin treatment.
Because of the strong reported correlation between en-
dogenous insulin secretion and 5′ ΔIRI on a non-dialysis
morning [5], endogenous insulin secretory function was
evaluated as 5′ ΔIRI [IRI(5)–IRI(0)], to compare func-
tion before and after alogliptin administration.
Statistical analyses
Statistical analysis was performed using SPSS version
17.0 (SPSS Inc, Chicago, IL, USA). All of the results are
expressed as mean and standard error of the mean. To
measure differences between the two groups, paired t
tests were conducted. Correlation between two groups
was determined using Pearson’s correlation coefficient.
All tests were two-tailed, and the significance was set at
P < 0.05.
Results
After 2 weeks of DPP-4i treatment, Glu(0) significantly
decreased by 24.1 ± 27.8 mg/dL (P = 0.023) (Table 2);
Glu(5) and Glu(15) decreased, but not significantly. Fig-
ure 1 shows the IRI (a) and 5′ΔIRI (b) before and after
DPP-4i. IRI(5) significantly increased by 8.8 ± 11.4 μU/mL
(P = 0.038); IRI(0) and IRI(15) did not change significantly.
Endogenous insulin secretory function had a strong rela-
tionship with 5′ΔIRI, which significantly increased by
Table 2 IVGTT before and after DPP-4i treatment (n = 10)
Before After P value
Fasting plasma glucose (mg/dl) 117 ± 22 107 ± 16 0.33
Pre-HD plasma glucose (mg/dl) 182 ± 15 145 ± 17 0.035
Glu(0) mg/dl 174 ± 20 150 ± 27 0.023
Glu(5) 228 ± 32 204 ± 37 0.065
Glu(15) 202 ± 27 182 ± 43 0.09
IRI(0) μU/ml 13.0 ± 5.8 15.4 ± 11.1 0.37
IRI(5) 14.6 ± 6.9 23.4 ± 16.6 0.038
IRI(15) 15.7 ± 7.8 19.6 ± 14.6 0.258
5′ΔIRI 1.61 ± 1.87 8.04 ± 8.07 0.015
15′ΔIRI 2.63 ± 2.75 4.24 ± 4.64 0.268
0.268 6.4 ± 2.9 5.7 ± 2.9 0.408
CPR(5) 6.1 ± 2.4 6.1 ± 2.8 0.976
CPR(15) 6.1 ± 2.4 6.1 ± 2.8 0.918
GLP-1 pmol/L 2.64 ± 0.76 6.63 ± 4.42 0.012
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cantly at any time. GLP-1 also significantly increased by
3.85 ± 3.85 nmol/nL (P = 0.012).
Discussion
In this study, 5′ΔIRI, which had strong relationship with
endogenous insulin secretory function [5], and GLP-1
were significantly increased after the DPP-4i treatment
on patients in the initial phase of the dialysis. Acute in-
sulin secretory response by IVGTT is to calm down
within 10 min, but the strength of the response is
strongly associated with the increase rate in glucose-by-
glucose load not only the glucose level itself [6]. There-
fore, evaluation of endogenous insulin secretory function
by IVGTT performed before lunch when glucose level
showed close to normal but not complete fasting such asa
Fig. 1 a IRI(5) significantly increased by 8.8 ± 11.4 μU/mL (P = 0.038); IRI(0) a
function had a strong relationship with 5′ ΔIRI, which significantly increasedin the morning is considered to be no problem, which
Gondo mentioned [5].
Our study has several limitations, such as the small
number of patients and performed in the incident
hemodialysis inpatients. In this phase, uremia, anemia,
malnutrition, CKD-MBD, and acidosis affect impaired
glucose metabolism. Our studies were performed on pa-
tients who already had some sessions of HD and whose
appetite was recovered presenting high postprandial
plasma glucose. But it was not a stable state such as the
maintenance of hemodialysis patients. In fact, urine
volume at first IVGTT was significantly more than that
at second IVGTT. We did not evaluate the exact re-
sidual kidney function, but considering the data of urine
volume and urine sugar qualitative testing at two points,
the differences in glycosuria between the two points was
considered to have no effect on impaired glucose metab-
olism. We also evaluated the influence of the initial
phase of the dialysis on glucose metabolism between the
two points in patients without DPP4i as control. There
was no remarkable difference in 5′ΔIRI between the two
points, and we think that the influence of the initial
phase of the dialysis was considered as no great impact
on our results.
Active vitamin D administration improves insulin
secretion from β cell in uremia. In our patients, three
patients used VDRA, but there was no patient who
started VDRA during our study. So even if our study
was performed in the HD initial phase, these effects
were considered to be minimal.
Incretin is produced by the gastrointestinal tract
following stimulation by the nutrients (e.g., glucose,
other carbohydrates, triglycerides, proteins) from a
meal. It enhances the glucose-dependent secretion of
insulin from beta cells, promotes beta cell prolifera-
tion, and inhibits beta cell apoptosis [7, 8]. Incretinb
nd IRI(15) did not change significantly. b Endogenous insulin secretory
by 6.43 ± 6.72 U/mL (P = 0.014)
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administration of glucose [9–11]. Therefore, oral
glucose elicits a higher insulin secretory response
than intravenous glucose, even for the same amount
of glucose [12] or similar concentrations following a
glucose load (i.e., isoglycemia) [13, 14]. This is called
the incretin effect.
Insulin secretion after an intravenous glucose load is
thought to be a result of released insulin particles that
directly bind to the cellular membrane of pancreatic beta
cells. The rapid insulin release is gradually augmented
with increasing GLP-1 [15].
Because of the incretin effect, we conducted an
IVGTT, rather than an oral glucose tolerance test, via an
external circulation circuit, which also eliminated the
need for multiple punctures for glucose infusion and
blood sampling. Although an intravenous glucose load is
thought to have less effect on incretin and insulin secre-
tion than an oral glucose load, both Glu and insulin
secretion significantly improved after DPP-4i treatment
in the present study.
Incretin is rapidly degraded by DPP-4. Therefore,
DPP-4i enhances the effect of insulin by controlling
the degradation of incretin. In the present study,
GLP-1 levels significantly increased after DPP-4i treat-
ment, even in the fasting state. The improvement in
endogenous insulin secretion following the 2-week
DPP-4i treatment in this study could be a result of
the effect of the elevated GLP-1 levels on the rapid
increase of insulin. Owing to the small sample size,
there was likely insufficient power for a significant
correlation between ΔGLP-1 (PostGLP-1-PreGLP-1)
and Δ5′ΔIRI (Post5′ΔIRI-Pre5′ΔIRI). The lack of sig-
nificant changes in CPR concentration after DPP-4i
treatment could also be explained by this rapid phase
of insulin release with IVGTT.
Valdarli et al. reported that DPP-4 inhibition aug-
mented insulin secretory responses both after oral glu-
cose and during isoglycemic intravenous glucose
infusions, with no net change in incretin effect, and that
DPP-4i induced changes in the incretin-related environ-
ment of islets that may persist overnight [16].
DPP-4i also inhibits glucagon release, leading to en-
hanced suppression of endogenous glucose production
[17]. Glucagon concentrations are suppressed with both
oral and intravenous glucose, although this occurs earlier
with intravenous glucose [18, 19]. In the present study,
we did not measure glucagon; therefore, we could not
determine if glucagon concentration was suppressed in
the early phase of IVGTT. This is certainly a limitation
of our study, and it deserves future research.
The inhibition by DPP-4 was associated with signifi-
cant increases in meal-stimulated plasma-active GLP-1
levels, which remained elevated from breakfast to justbefore lunch, when the measurements were taken,
without returning to baseline levels.
In actual conditions, ingested food may stimulate
incretin secretion by the gastrointestinal tract, which
then enhances insulin secretion from the beta cells, and
this may have an additive effect on the improvement in
glucose homeostasis observed in the present study with
HD patients with T2DM. Our results also support the
usefulness of DPP4i in HD patients by the improvement
of β cell function. It could be one of the causes that HD
patients could withdraw from insulin treatment or
decrease the amount of insulin by DPP4i.
Conclusions
DPP-4i (alogliptin) treatment resulted in improvements
in the endogenous insulin secretory function of HD pa-
tients with T2DM, primarily owing to an augmentation
of the insulin secretory response, even with intravenous
administration of glucose.
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